BUSINESS
Kyowa Kirin to Carry Out Novel Target Discovery Using US Firm’s AI-Platform
Kyowa Kirin said on December 9 that the company and US-based InveniAI, which specializes in the application of AI and machine learning, have expanded their existing joint research collaboration for novel target discoveries by harnessing the US company’s AI-platform. The…
To read the full story
Related Article
- Kyowa Kirin, InveniAI Expand Collaboration in AI-Driven Drug Discovery
December 23, 2021
BUSINESS
- PMP Returns Slam Drug Makers' Leading Products, Prazaxa Cut 45%: Jiho Poll
March 13, 2026
- Lilly to Invest Additional 20 Billion Yen in Japan's Seishin Plant
March 13, 2026
- Fujifilm Invests in Austria’s Valanx Biotech to Boost ADC Technology
March 13, 2026
- Merck, CDMO Cyto-Facto Join Hands on Cell and Gene Therapy
March 13, 2026
- Anti-PD-1 Agonist Antibody Enters PI in Australia for Autoimmune Diseases: Meiji
March 13, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





